Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
Century Therapeutics (IPSC) Stock Price & Analysis
68 Followers
IPSC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.81 - $14.00
Previous Close$3.17
Volume47.23K
Average Volume (3M)122.63K
Market Cap
$188.87M
Enterprise Value-$11.13M
Total Cash (Recent Filing)$251.47M
Total Debt (Recent Filing)$51.47M
Price to Earnings (P/E)-1.5
Beta0.94
Next Earnings
Aug 10, 2023EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding59,580,817
10 Day Avg. Volume91,014
30 Day Avg. Volume122,626
Standard Deviation0.15
R-Squared0.05
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)110.16
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.90
Enterprise Value/Gross Profit-2.14
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$17.75Price Target Upside459.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Century Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $2.81 and its highest was $14.00 in the past 12 months.
What is Century Therapeutics’s market cap?
Currently, no data Available
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is Aug 10, 2023 which is in 68 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on May 11, 2023. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.524 by -$0.006.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -$0.54.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 59,580,820 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.524. Following the earnings report the stock price went down -1.749%.
Which hedge fund is a major shareholder of Century Therapeutics?
Among the largest hedge funds holding Century Therapeutics’s share is Baker Bros Advisors LP. It holds Century Therapeutics’s shares valued at 4M.
---
Century Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.75 (459.94% Upside)
$17.75 (459.94% Upside)
Hedge Fund Trend
Decreased
By 11.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.97%
12-Months-Change
Fundamentals
Return on Equity
-37.56%
Trailing 12-Months
Asset Growth
-17.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Century Therapeutics
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
---
Top 5 ETFs holding IPSC
Vanguard Total Stock Market ETF
$1.96M
iShares Biotechnology ETF
$554.98K
Vanguard Health Care ETF
$226.98K
iShares NASDAQ US Biotechnology UCITS ETF
$96.90K
Schwab U.S. Broad Market ETF
$35.35K
Up to five ETFs with an Outperform Smart Score that hold IPSC. The ETFs are listed according to market value of IPSC within the ETF
---
---